156 related articles for article (PubMed ID: 10029235)
1. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models.
Ito Y; Fujita M; Shimada S; Watanabe Y; Okada T; Kusuoka H; Tohyama M; Nishimura T
Synapse; 1999 Mar; 31(3):178-85. PubMed ID: 10029235
[TBL] [Abstract][Full Text] [Related]
2. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter.
Jaber M; Dumartin B; Sagné C; Haycock JW; Roubert C; Giros B; Bloch B; Caron MG
Eur J Neurosci; 1999 Oct; 11(10):3499-511. PubMed ID: 10564358
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.
Reveron ME; Savelieva KV; Tillerson JL; McCormack AL; Di Monte DA; Miller GW
Neurotoxicology; 2002 Oct; 23(4-5):611-9. PubMed ID: 12428733
[TBL] [Abstract][Full Text] [Related]
6. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.
Harrington KA; Augood SJ; Kingsbury AE; Foster OJ; Emson PC
Brain Res Mol Brain Res; 1996 Feb; 36(1):157-62. PubMed ID: 9011752
[TBL] [Abstract][Full Text] [Related]
8. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
9. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
10. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat.
Fujita M; Nishino H; Kumazaki M; Shimada S; Tohyama M; Nishimura T
Brain Res Mol Brain Res; 1996 Jul; 39(1-2):127-36. PubMed ID: 8804721
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.
Drandarevski N; Marburger A; Walther D; Reum T; Uh G; Morgenstern R
J Neural Transm (Vienna); 2001; 108(2):141-51. PubMed ID: 11314769
[TBL] [Abstract][Full Text] [Related]
12. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
Guttman M; Stewart D; Hussey D; Wilson A; Houle S; Kish S
Neurology; 2001 Jun; 56(11):1559-64. PubMed ID: 11402115
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.
Wilson JM; Levey AI; Bergeron C; Kalasinsky K; Ang L; Peretti F; Adams VI; Smialek J; Anderson WR; Shannak K; Deck J; Niznik HB; Kish SJ
Ann Neurol; 1996 Sep; 40(3):428-39. PubMed ID: 8797532
[TBL] [Abstract][Full Text] [Related]
14. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration.
Lu W; Wolf ME
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):137-48. PubMed ID: 9387873
[TBL] [Abstract][Full Text] [Related]
15. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
Brooks DJ; Frey KA; Marek KL; Oakes D; Paty D; Prentice R; Shults CW; Stoessl AJ
Exp Neurol; 2003 Nov; 184 Suppl 1():S68-79. PubMed ID: 14597329
[TBL] [Abstract][Full Text] [Related]
16. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.
Lee WY; Chang JW; Nemeth NL; Kang UJ
J Neurosci; 1999 Apr; 19(8):3266-74. PubMed ID: 10191339
[TBL] [Abstract][Full Text] [Related]
17. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
[TBL] [Abstract][Full Text] [Related]
19. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs.
Zucker M; Weizman A; Harel D; Rehavi M
Neuropsychobiology; 2001; 44(4):187-91. PubMed ID: 11702019
[TBL] [Abstract][Full Text] [Related]
20. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.
Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI
Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
